This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
1g | $290 | Check With Us |
2g | $520 | Check With Us |
25g | $875 | Check With Us |
Cat #: V0104 CAS #: 870281-82-6 Purity ≥ 98%
Description: Idelalisib (CAL-101, GS-1101; trade name Zydelig), an approved anticancer drug, is a potent and selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; it has 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 415.42 |
---|---|
Molecular Formula | C22H18FN7O |
CAS No. | 870281-82-6 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
Solubility In Vitro | DMSO: 83 mg/mL warming (199.79 mM)r |
Water:<1 mg/mL (slightly soluble or insoluble)r | |
Ethanol: 23 mg/mL (55.36 mM) | |
Solubility In Vivo | 30% PEG 400 (dissolve first)+0.5% Tween 80+5% Propylene glycol: 30 mg/mL |
SMILES Code | O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5 |
Synonyms | CAL101; CAL 101; CAL-101; GS1101; GS 1101; GS-1101, Idelalisib |
Protocol | In Vitro | Idelalisib (CAL-101; GS-1101) is a highly selective and potent p110δ inhibitor (EC50=8 nM). Greater selectivity (400- to 4000-fold) is seen against related kinases C2β, hVPS34, DNA-PK, and mTOR, whereas no activity is observed against a panel of 402 diverse kinases at 10 μM. CAL-101 reduces PDGF-induced pAkt by only 25% at 10 μM. Idelalisib (CAL-101) inhibits LPA-induced pAkt with an EC50 of 1.9 μM. Idelalisib (CAL-101) blocks FcϵRI p110δ-mediated CD63 expression with an EC50 of 8 nM, whereas formyl-methionyl-leucyl-phenylalanine activation of p110γ is inhibited with an EC50 of 3 μM. Thus, in cell-based assays, CAL-101 has 240- to 2500-fold selectivity for p110δ over the other class I PI3K isoforms. |
---|---|---|
In Vivo | A significant reduction is observed in the CD11b+Ly6G+ neutrophils from brain homogenates of bothp110δD910A/D910A mice and Idelalisib (CAL-101) (40 mg/kg, i.v.) post-treated mice. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 2.4072 mL | 12.0360 mL | 24.0720 mL | 48.1440 mL |
5mM | 0.4814 mL | 2.4072 mL | 4.8144 mL | 9.6288 mL |
10mM | 0.2407 mL | 1.2036 mL | 2.4072 mL | 4.8144 mL |
20mM | 0.1204 mL | 0.6018 mL | 1.2036 mL | 2.4072 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.